Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK), a research-based pharmaceutical and healthcare company, has appointed Patrick Vallance as senior vice president of medicines discovery and development and as a member of the company’s corporate executive team both with effect from July 1, 2010.
Subscribe to our email newsletter
Prior to joining GSK in 2006, Patrick was a clinical academic and led the division of medicine at UCL. He has over 20 years of experience of clinical medicine and has an international reputation as a vascular biologist and clinician scientist. He was elected to the Academy of Medical Sciences in 1999, and subsequently became its Registrar before leaving to join GSK.
Andrew Witty, CEO of GSK, said: “Patrick has a deep level of scientific and medical acumen, which coupled with his proven management skills, mean he is well placed to bring further R&D perspective to GSK’s leadership team.
“This appointment aligns with the company’s drive to increase R&D productivity and deliver more products of value. I look forward to working with Patrick in his new role and welcome him to the executive team.”